Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lesterhuis, W Joost ^a,b   Rinaldi, Catherine ^a,b   Jones, Anya ^c   Rozali, Esdy N ^a,b   Dick, Ian M ^a,b   Khong, Andrea ^a,b   Boon, Louis ^d   Robinson, Bruce W ^a,b   Nowak, Anna K ^b,e   Bosco, Anthony ^c   Lake, Richard A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d BIOCEROS   (Netherlands)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DRUG COMBINATION;

ANIMAL; BAGG ALBINO MOUSE; DRUG COMBINATION; DRUG POTENTIATION; DRUG REPOSITIONING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MESOTHELIOMA; REMISSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG COMBINATIONS; DRUG REPOSITIONING; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; IMMUNOTHERAPY; MESOTHELIOMA; MICE, INBRED BALB C; REMISSION INDUCTION;

EID: 84937459433     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12298     Document Type: Article

References (50)

1. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New Engl J Med 363, 711-723, (2010).
2. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 366, 2443-2454 (2012).
3. Lesterhuis, W. J., Haanen, J. B. & Punt, C. J. Cancer immunotherapy - revisited. Nat Rev Drug Discov 10, 591-600 (2011).
4. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu Rev Med 65, 185-202 (2014).
5. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. The New Engl J Med 369, 122-133 (2013).
6. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30, 2046-2054 (2012).
7. Barabasi, A. L. & Albert, R. Emergence of scaling in random networks. Science 286, 509-512 (1999).
8. Oltvai, Z. N. & Barabasi, A. L. Systems biology. Life's complexity pyramid. Science 298, 763-764 (2002).
9. Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010).
10. Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat Genet 37, 382-390 (2005).
11. Lesterhuis, W. J., Bosco, A. & Lake, R. A. Comment on "drug discovery: turning the titanic". Sci Transl Med 6, 229le222 (2014).
12. Lesterhuis, W. J. et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE 8, e61895 (2013).
13. van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194, 481-489 (2001).
14. Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823-832 (2001).
15. Grosso, J. F. & Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 13, 5 (2013).
16. Oldham, M. C., Horvath, S. & Geschwind, D. H. Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proc. Natl. Acad. Sci. USA. 103, 17973-17978 (2006).
17. Horvath, S. et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc. Natl. Acad. Sci. USA. 103, 17402-17407 (2006).
18. Bosco, A., McKenna, K. L., Firth, M. J., Sly, P. D. & Holt, P. G. A network modeling approach to analysis of the Th2 memory responses underlying human atopic disease. J Immunol 182, 6011-6021 (2009).
19. Bosco, A., Ehteshami, S., Panyala, S. & Martinez, F. D. Interferon regulatory factor 7 is a major hub connecting interferon-mediated responses in virus-induced asthma exacerbations in vivo. J Allergy Clin Immunol 129, 88-94 (2012).
20. Singh, S. & Gupta, A. K. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 67, 1211-1224 (2011).
21. Hartwell, L. H., Hopfield, J. J., Leibler, S. & Murray, A. W. From molecular to modular cell biology. Nature 402, C47-52 (1999).
22. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
23. Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523-530 (2014).
24. Hall, J. A., Grainger, J. R., Spencer, S. P. & Belkaid, Y. The role of retinoic acid in tolerance and immunity. Immunity 35, 13-22 (2011).
25. Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832-844 (2014).
26. Basu, R. et al. IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. Nat Immunol 16, 286-295 (2015).
27. Heinecke, J. L. et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci USA 111, 6323-6328 (2014).
28. Grimm, E. A., Sikora, A. G. & Ekmekcioglu, S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 19, 5557-5563 (2013).
29. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683 (2004).
30. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-715 (2004).
31. Marzo, A. L. et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 162, 5838-5845 (1999).
32. Nowak, A. K. et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170, 4905-4913 (2003).
33. Hochreiter, S., Clevert, D. A. & Obermayer, K. A new summarization method for Affymetrix probe level data. Bioinformatics 22, 943-949 (2006).
34. Dai, M. et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucl Acids Res 33, e175 (2005).
35. Talloen, W. et al. I/NI-calls for the exclusion of non-informative genes: a highly effective filtering tool for microarray data. Bioinformatics 23, 2897-2902 (2007).
36. Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network analysis. Stat. Appl. Genet. Mol. Biol. 4, Article17 (2005).
37. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
38. Piotrovskij, V. et al. Dose-ranging study of NG-nitro-L-arginine pharmacokinetics in rats after bolus intravenous administration. Xenobiotica 24, 663-669 (1994).
39. Pipili-Synetos, E. et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 116, 1829-1834 (1995).
40. Wang, S. et al. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood 114, 600-607 (2009).
41. Li, Y. et al. VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2, 296-308 (2010).
42. U.S. National Library of Medicine, http://chem.sis.nlm.nih.gov/chemidplus/rn/1084-65-7 (2012)(Date of access: 24/06/2015).
43. Lawton, W. J. & Chatterjee, K. in Cardiac Drugs (eds K. Chatterjee & E. J. Topol) 72-157 (Jaypee Brothers Medical Publishers Ltd., 2013).
44. Ito, K. et al. Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein. Drug Metabol Pharmacokinet 24, 108-113 (2009).
45. Ying, H. et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5, 2158-2164 (2006).
46. Satapathy, S. K. et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med 17, 599-606 (2011).
47. Franca, D. S. et al. B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. Eur J Pharmacol 421, 157-164 (2001).
48. Arguello, F. et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490 (1998).
49. Fujiwara, Y. et al. Triterpenoids isolated from Zizyphus jujuba inhibit foam cell formation in macrophages. J. Agric. Food Chem. 59, 4544-4552 (2011).
50. Marzo, A. L., Lake, R. A., Robinson, B. W. & Scott, B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59, 1071-1079 (1999).